Stem Cell Transplant

What is a stem cell transplant?

A stem cell transplant replaces diseased, damaged or depleted blood-forming cells with healthy haematopoietic stem cells. It is used mainly for blood cancers such as leukaemia, lymphoma and multiple myeloma, and for disorders in which the bone marrow fails or produces abnormal cells. It is also the most established form of stem cell therapy in routine clinical use: a treatment with decades of accumulated evidence behind it, delivered under strict protocols in specialised haematology and transplant units rather than as an experimental procedure.

If you have been told that you or someone close to you may need a transplant, the word itself raises hard questions. How demanding is the treatment? What are the risks? How long does recovery take? Is it better to be treated close to home, or at a centre that performs transplants every week? These questions deserve straight answers, and this page gives them as directly as the evidence allows. Understanding stem cells and treatment pathways built around them makes each stage of the decision easier to weigh — and easier to discuss with the haematologists who know your case in detail.

A transplant is not a single operation performed on one day. It is a planned medical pathway: confirming the diagnosis, selecting the donor or stem cell source, giving conditioning therapy, infusing the cells, preventing infection while the new marrow takes hold, and following you closely for months afterwards. For some diseases, transplant may offer durable disease control when other treatments are unlikely to be sufficient. For others, it restores bone marrow function after high-dose therapy, or replaces a marrow system that is failing or producing abnormal cells. Each stage has a defined purpose, and each involves decisions you should understand before you commit.

What are stem cells?

Stem cells, in this context, are haematopoietic stem cells: immature blood-forming cells that live mainly in the bone marrow and mature into red blood cells, white blood cells and platelets. Every blood cell in your body descends from them, which is why replacing or restoring them can rebuild an entire blood and immune system. For transplant purposes they can be collected from three sources — the bloodstream after mobilisation medication, the bone marrow itself, or umbilical cord blood donated at birth. Which source is used depends on the diagnosis, the donor situation and the transplant plan. These are not embryonic stem cells, and haematopoietic transplant should not be confused with regenerative treatments that borrow the same vocabulary but rest on far thinner evidence.

How does a stem cell transplant work?

A stem cell transplant works by rebuilding your blood and immune system from healthy stem cells after intensive treatment. Most patients first receive conditioning therapy, which may include high-dose chemotherapy and sometimes radiation. Conditioning can serve up to three purposes: it helps destroy remaining cancer cells, it suppresses your immune system so that donor cells can take hold, and it creates space in the bone marrow for the new cells to grow. The stem cells are then infused through a vein, much like a blood transfusion. Over the following days and weeks, the cells travel to the bone marrow and begin producing new blood cells. This process is called engraftment, and it is the biological turning point of the whole treatment.

In donor transplants there is a second mechanism at work. The donor’s immune cells can recognise and attack residual malignant cells — an effect known as graft-versus-tumour activity, and one of the main reasons a donor transplant is chosen for certain diseases. The same immune activity can also react against healthy tissue, causing graft-versus-host disease, which is why careful matching, preventive medication and close monitoring are built into every donor transplant protocol.

Stem cell therapy and stem cell transplant: what is the difference?

Stem cell therapy is an umbrella term; haematopoietic stem cell transplantation — the treatment this page describes — is the form with the strongest evidence base and the clearest indications. Online, the words stem cells, cell therapy, graft, regenerative medicine and transplant appear side by side and are often used loosely, which creates real confusion for patients. Some applications, such as cardiac stem cell therapy, are studied for entirely different purposes and sit at a different point on the evidence spectrum. Others exist mainly as marketing language.

Clinics around the world advertise stem cell therapy for joint pain, ageing, neurological disease and much else, often with little supporting data. The transplant described here is different in kind: it has defined indications, regulated cell products, published protocols and decades of clinical practice behind it. Knowing the distinction protects you from both false hope and unnecessary fear.

Types of stem cell transplant

There are two main types of stem cell transplant, defined by whose cells are used. The right type for you depends on the diagnosis, disease status, prior treatments, age, general health, organ function, genetic risk features, donor availability, and the balance between expected benefit and risk. That judgement is made in a detailed transplant consultation, often with haematology and transplant specialists reviewing the case together rather than one doctor deciding alone.

Autologous stem cell transplant

An autologous stem cell transplant uses your own stem cells, collected in advance, frozen, and returned to you after high-dose treatment. It is commonly used in multiple myeloma and in some lymphomas. The logic is straightforward: high-dose chemotherapy can be more effective against certain diseases, but at doses the bone marrow could not survive on its own. Reinfusing your previously collected cells rescues blood production afterwards. Because the cells are your own, there is no rejection and no graft-versus-host disease, and hospital admissions are generally shorter than for donor transplants. What an autologous transplant does not provide is a donor immune effect against the disease.

Allogeneic stem cell transplant

An allogeneic stem cell transplant uses stem cells from another person: a matched sibling, a matched unrelated donor found through international registries, a haploidentical (half-matched) family donor, or in some cases umbilical cord blood. It is considered for diseases in which replacing the immune and marrow system may help control or eliminate malignant or abnormal cells — the donor’s immune system becomes part of the treatment. That benefit comes with additional demands: the risk of graft-versus-host disease, immune-suppressing medication, more intensive monitoring, and usually a longer period living near the transplant centre after discharge. Choosing between donor options is a specialist decision shaped by HLA compatibility, donor health, urgency, disease characteristics and the centre’s experience with each approach.

Is a bone marrow transplant the same as a stem cell transplant?

For most practical purposes, yes: a bone marrow transplant is a stem cell transplant in which the cells are collected directly from the donor’s marrow rather than from circulating blood. Historically this was the standard collection method, which is why the older name survives — and why in clinical literature you will still see it abbreviated to BM transplantation. Today, most grafts are collected from peripheral blood after mobilisation medication, with marrow harvest and cord blood reserved for situations where they offer an advantage. Whatever the source, the biology after infusion is the same: the cells home to the bone marrow and rebuild blood production there.

Who may need a stem cell transplant?

Transplant may be recommended when a disease is high-risk, relapsed, resistant to standard therapy, or associated with bone marrow failure. It may also be considered when the expected benefit of high-dose therapy, donor immune effect or marrow replacement outweighs the risks of intensive treatment. Not every patient with a blood cancer or marrow disorder needs a transplant. In some conditions, newer medications, targeted therapies, immunotherapies or careful monitoring are more appropriate, and a transplant evaluation exists precisely to establish where — or whether — the procedure fits within the broader treatment plan.

Patients referred for transplant assessment often have symptoms related to abnormal blood cell production: persistent fatigue, shortness of breath, frequent infections, unexplained fevers, easy bruising, bleeding gums, bone pain, swollen lymph nodes, night sweats, weight loss or recurrent anaemia. Others have few symptoms at all, and the possible need for transplant emerges from blood tests, bone marrow biopsy results, imaging, cytogenetic or molecular findings, or the way the disease responded to previous treatment.

Diagnosis and transplant planning typically involve a combination of tests: complete blood counts, blood chemistry, bone marrow aspiration and biopsy, flow cytometry, cytogenetic analysis, molecular testing, imaging such as CT, PET-CT or MRI when indicated, heart and lung evaluation, infectious disease screening, kidney and liver function tests, dental assessment, and fertility or reproductive counselling where relevant. For allogeneic transplant, tissue typing — known as HLA typing — is performed for you and for potential donors.

Common situations that lead to a transplant consultation include newly diagnosed high-risk leukaemia, leukaemia in remission after induction therapy, lymphoma that has returned after treatment, multiple myeloma responding to initial therapy, myelodysplastic syndromes with a significant risk of progression, severe aplastic anaemia, inherited marrow failure syndromes, and selected immune or metabolic disorders. Timing can be critical. Some patients are evaluated early even though transplant is not planned immediately, so that donor options and treatment strategy are ready if the disease course changes.

Conditions treated with stem cell transplant

Transplant can be part of treatment for a broad range of haematologic diseases, and the indications continue to evolve as drug therapies, cellular therapies, genetic testing and supportive care improve. A transplant centre evaluates each case individually, because the same diagnosis can behave very differently from one patient to another.

In acute leukaemias — acute myeloid leukaemia and acute lymphoblastic leukaemia — allogeneic transplant may be considered when genetic features, measurable residual disease results or response to therapy suggest a higher risk of relapse. In some patients, transplant is performed while the disease is in remission, to reduce the likelihood of recurrence. In others, additional therapy is needed first to bring the disease under better control before transplant becomes a sensible option.

In lymphomas, autologous transplant is often used when certain types of Hodgkin or non-Hodgkin lymphoma return or do not respond fully to first-line therapy. It allows higher-dose chemotherapy than the body could otherwise tolerate, followed by reinfusion of your previously collected cells. Allogeneic transplant is considered in selected lymphoma cases, particularly where disease behaviour, prior therapies and the potential donor immune effect make it a reasonable choice.

In multiple myeloma, autologous transplant remains an important option for many eligible patients, usually after initial therapy has reduced the burden of disease. The intent is to deepen the response and extend the period of disease control, often followed by maintenance treatment. Eligibility depends on overall fitness rather than age alone — a point worth remembering if you have been told elsewhere that you are “too old” without a formal assessment.

For bone marrow failure disorders — aplastic anaemia, inherited marrow failure syndromes and selected myelodysplastic syndromes — transplant can replace a marrow system that cannot produce adequate blood cells, and in myelodysplastic syndromes it may also address the risk of progression to acute leukaemia. Transplant is also used for certain non-malignant blood disorders, immune deficiencies, metabolic disorders and haemoglobinopathies in carefully selected patients, especially when the disease is severe and other treatments are inadequate.

Transplant is not the only cellular treatment in modern haematology. For some relapsed blood cancers, CAR-T cell therapy — which re-engineers a patient’s own immune cells rather than replacing the marrow — may be considered instead of, before, or after transplant. Immunotherapy and targeted drug therapy have also changed the calculus for several diagnoses. Part of a good transplant evaluation is asking honestly whether one of these alternatives serves you better.

How is a stem cell transplant done?

A stem cell transplant is done in planned stages over weeks to months. The sequence for most patients looks like this:

• 1. Evaluation. The team confirms the diagnosis, assesses disease risk and organ function, and decides whether transplant is appropriate and which type.
• 2. Donor search or cell collection. For allogeneic transplant, HLA typing and donor identification; for autologous transplant, mobilisation and collection of your own cells.
• 3. Preparation. Central line placement, dental review, infection screening, medication review and counselling about the admission.
• 4. Conditioning therapy. High-dose treatment given over several days, tailored in intensity to your disease and fitness.
• 5. Infusion — Day 0. The stem cells are given through the central line, much like a transfusion.
• 6. Engraftment. Days to weeks of close inpatient monitoring while blood counts fall and then recover.
• 7. Follow-up. Frequent outpatient visits, medication adjustment and long-term monitoring after discharge.

Pre-transplant assessment

Everything begins with a comprehensive consultation. The medical team reviews the diagnosis, previous treatments, pathology reports, imaging results, genetic and molecular findings, current medications, past infections, organ function and overall performance status. This stage determines whether transplant is appropriate now, which type is best, and which risks need specific planning. For international patients, most established programmes review medical records before travel, so that a preliminary opinion exists before anyone books a flight — a sensible expectation to hold of any centre you consider.

Donor search and HLA matching

If an allogeneic transplant is being considered, donor search and HLA matching are central steps. Siblings are usually tested first, but many patients do not have a fully matched sibling. In those cases the team evaluates unrelated donor registries, partially matched (haploidentical) family donors, or cord blood units. The choice is shaped by HLA compatibility, donor health and availability, urgency of transplant, disease characteristics and the centre’s experience with each approach. Donor searches take time — sometimes considerable time — which is one of the strongest arguments for early evaluation.

Stem cell mobilisation and collection

For autologous transplant, your stem cells are collected before high-dose therapy. You typically receive medications that move stem cells from the bone marrow into the bloodstream, a process known as mobilisation. The cells are then collected through apheresis: blood is drawn through a vein or central line, passed through a machine that separates the stem cells, and returned to your body in the same session. The collected cells are tested, counted, processed and frozen until the transplant. Donor cells are collected in a similar way, or harvested directly from the marrow under anaesthesia when that source is preferred.

Conditioning therapy

Conditioning intensity varies deliberately. Some patients receive myeloablative conditioning — the stronger form, designed to eliminate marrow function more completely. Others receive reduced-intensity or non-myeloablative conditioning, chosen when age, organ function, disease type or prior treatment history makes a gentler approach safer. Conditioning may consist of chemotherapy alone, or chemotherapy combined with radiation therapy in selected cases. Before it begins, the team explains what to expect during the weeks of low blood counts: fatigue, nausea, mouth sores, diarrhoea, appetite changes, hair loss, fever monitoring, transfusion needs and infection precautions. Knowing what is normal for this phase makes it considerably less frightening when it happens.

What happens on the day of the transplant?

The infusion itself is usually the least dramatic part of the whole pathway. The cells are given through the central line or a vein while nurses and physicians monitor vital signs and watch for reactions. The day of infusion is called Day 0, and every milestone afterwards is counted from it. Depending on the product, the infusion takes anywhere from a short time to several hours. The genuinely intensive phase comes afterwards, as you wait for the new marrow to establish itself.

Engraftment and the early weeks

During the early post-transplant period you are monitored closely for infection, bleeding, anaemia, fluid balance, kidney and liver function, nutrition, pain and medication effects. Blood tests are frequent. Transfusions, antibiotics, antifungal or antiviral medication, growth factors, intravenous fluids, nutritional support and symptom-control medication are used as needed. In allogeneic transplant, the team also watches for graft-versus-host disease, and preventive medication is given according to the transplant protocol. Engraftment — the point at which the new cells begin producing blood — commonly arrives during the early weeks, though timing differs between patients and transplant types.

Modern transplant units rely on an infrastructure most patients never see: high-resolution tissue typing, molecular tests that measure residual disease, flow cytometry, advanced imaging, infectious disease surveillance, organ function testing, specialised blood bank support, controlled stem cell processing and cryopreservation, and electronic medication and monitoring systems. Protective inpatient environments, strict hygiene protocols, antimicrobial stewardship and experienced transplant nursing matter just as much. Technology counts most when it is integrated into a disciplined clinical pathway and interpreted by teams who manage transplant patients every day — not as a list of equipment on a website.

The length of hospital stay varies with transplant type, conditioning intensity, complications and the speed of engraftment. Autologous admissions are often shorter than allogeneic ones, but both require close follow-up after discharge. Many patients need to remain near the transplant centre for a period — particularly after allogeneic transplant — because infections, medication adjustments and graft-versus-host disease can emerge after leaving the ward. Recovery continues for months, and immune reconstitution can take considerably longer.

Why timing matters

Stem cell transplant is time-sensitive for many conditions. In aggressive blood cancers, the safest and most effective moment for transplant is often when the disease is in remission or at its lowest measurable level. Delay can allow the disease to return, develop resistance, or affect organs and general health in ways that make transplant harder to tolerate. Early referral does not mean immediate transplant; it means you and the medical team understand the options before an urgent decision is forced on you.

For patients who may need an allogeneic transplant, donor identification takes time. HLA typing, donor testing, infectious screening, collection planning and coordination with registries or family donors have to happen in careful sequence. Starting early prevents avoidable delays if transplant becomes necessary. It also buys time to optimise your condition — treating infections, improving nutrition, evaluating heart and lung function — and to arrange the practical side: travel, accommodation, a caregiver, and work or family responsibilities.

Waiting too long can narrow the options. Patients with relapsed or refractory disease may need additional chemotherapy or other treatment before transplant, and the ability to tolerate that treatment depends on marrow reserve, organ function and overall strength. Bone marrow failure disorders can lead to repeated transfusions, infections, bleeding, iron overload or immune complications the longer they run. In some inherited and non-malignant conditions, prolonged illness causes cumulative organ damage that raises transplant risk later.

Acting early also leaves room for a second opinion. For complex haematology diagnoses, an independent review can clarify whether transplant is truly indicated, which type is recommended, whether further testing is needed, and how transplant compares with the alternatives. That clarity is especially valuable if you are weighing care in your home country against treatment abroad, where decisions cross healthcare systems and the stakes of getting the sequence right are high.

Benefits of stem cell transplant

The potential benefits depend on the diagnosis, disease status, transplant type, donor match and your overall health — which is why they are best read as possibilities to discuss, not promises.

Benefit	What It Means for You
Disease control in high-risk conditions	For selected blood cancers and marrow disorders, transplant may offer a stronger treatment approach when standard therapy alone is unlikely to provide durable control.
Replacement of damaged bone marrow	Healthy stem cells can restore blood cell production after high-dose therapy or in conditions where the marrow is failing.
Use of donor immune effect	In allogeneic transplant, donor immune cells may help recognise and control remaining malignant cells in certain diseases.
Deeper response after intensive therapy	In conditions such as multiple myeloma or relapsed lymphoma, autologous transplant can support recovery after high-dose treatment intended to reduce disease burden.
Structured long-term monitoring	Transplant programmes follow patients closely for relapse, infection risk, graft-versus-host disease, medication effects and immune recovery.

Recovery after a stem cell transplant

Recovery varies widely between patients and transplant types, so treat any timeline as a map, not a schedule. The pattern most patients experience runs from close inpatient monitoring, through the low-count period, to engraftment, discharge, and a long tail of outpatient follow-up while the immune system rebuilds. The table below describes what many patients can generally expect.

Time Period	What Patients Can Expect
Day 1	The first day after infusion usually involves close monitoring, supportive medications, blood tests, and preparation for the period when blood counts will be low.
First Week	Blood counts often decline. Fatigue, nausea, mouth soreness, appetite changes, fever risk and transfusion needs may occur. Infection precautions are especially important.
First Month	Engraftment commonly occurs during the early weeks, though timing differs. Patients may be discharged when stable but continue frequent outpatient visits and medication monitoring.
First Three Months	Energy gradually improves, but infection risk remains. Allogeneic transplant patients are monitored carefully for graft-versus-host disease and immune-suppressive medication effects.
Longer Term	Immune recovery continues over months or longer. Follow-up may include vaccination planning, disease monitoring, survivorship care, nutrition, rehabilitation and coordination with doctors at home.

After discharge, most programmes ask patients to stay within reach of the centre for a defined period, follow food and hygiene precautions, and report fevers or new symptoms to the transplant team as part of the agreed discharge plan. Vaccination schedules are rebuilt over time under the team’s direction, because the transplant effectively resets parts of immune memory. Returning to work, travel and normal routines happens gradually and at different speeds for different people; the team will tell you what is realistic for your situation rather than a generic average.

What influences the outcome of a stem cell transplant?

Outcomes are shaped by many factors, and no responsible transplant team measures success in a single dimension. The first consideration is the underlying disease: diagnosis, genetic risk profile, measurable residual disease, response to prior therapy, disease stage, and the time from diagnosis to transplant all matter. A patient whose disease is in remission before transplant faces a different risk landscape than a patient with active or resistant disease.

The type of transplant matters too. Autologous and allogeneic transplants have different goals, risks and recovery patterns. In autologous transplant, the key issues are the quality of the disease response beforehand, the adequacy of stem cell collection, organ function, and recovery from high-dose therapy. In allogeneic transplant, donor selection, HLA match, conditioning regimen, graft source, graft-versus-host disease prevention, infection monitoring and immune recovery are the dominant variables.

Your health at the time of transplant strongly affects how well you tolerate it. Heart, lung, kidney and liver function are assessed carefully. Diabetes, prior infections, nutritional status, mobility, smoking history, dental health and previous cancer treatments can all influence complications and the speed of recovery. Age is considered — but it is not the deciding measure. Transplant decisions rest on physiological fitness, disease risk and whether treatment can be tailored safely, which is why formal assessment beats assumptions.

A good result also depends on supportive care. During the weeks of low immunity, rapid response to fever, appropriate antimicrobial treatment, transfusion support, nutrition, pain control and careful medication management make a real difference. Experienced transplant nurses, pharmacists, infectious disease specialists, intensive care teams, dietitians, rehabilitation professionals and psychosocial support staff all contribute to safety — a transplant is a team result, not a single physician’s.

Adherence after discharge carries equal weight. Taking medication exactly as the transplant team prescribes, attending follow-up visits, keeping to food and hygiene precautions, avoiding risky exposures during immune recovery, and checking with the team before any vaccine or new medicine — these habits protect the result the hospital phase achieved. For international patients, clear discharge documentation and communication between the transplant centre and your local physicians are essential so care continues seamlessly after you return home.

Finally, do not underestimate psychological readiness and caregiver support. Transplant is physically and emotionally demanding. Isolation, uncertainty, changes in appetite and sleep, financial pressure and anxiety about recurrence are common and normal. A reliable caregiver, access to interpreters when needed, and a team that communicates plainly help patients move through treatment with more confidence and fewer preventable difficulties.

How much does a stem cell transplant cost?

There is no single honest figure, because the cost of a stem cell transplant is driven by variables that differ enormously between patients. The largest drivers are the type of transplant — autologous pathways are generally simpler than allogeneic ones — the extent of any donor search and registry involvement, the conditioning regimen, the length of the hospital admission, whether complications arise, the medications needed during and after admission, and the duration of follow-up. The country and the individual hospital add further variation on top.

Because of this, a headline number attached to “a transplant” tells you very little. What serves you better is an itemised estimate for your specific case: pre-transplant evaluation and testing, donor search and cell collection where relevant, cell processing and storage, the admission itself, medications, and a defined period of outpatient follow-up. It should also state clearly how complications are handled financially, since they are the least predictable element of any transplant. Whoever is paying — you, an insurer or a national health system — that level of transparency is a reasonable thing to expect before treatment begins.

Stem cell transplant care at Acibadem

Stem cell transplant requires coordination across many specialties, and Acibadem organises it that way. Haematologists, transplant physicians, medical oncologists, radiation oncologists where needed, infectious disease specialists, pathologists, radiologists, laboratory medicine experts, intensive care physicians, pharmacists, nurses, dietitians and rehabilitation teams may all be involved in a single patient’s pathway. Complex cases can be reviewed in specialist boards, where diagnostic findings, disease biology, treatment response, donor options and transplant timing are discussed in a structured way — particularly relevant if you have already been treated in another country and need an independent view of the next step.

Treatment decisions follow internationally aligned protocols while remaining personal. That includes selection of conditioning therapy, infection prevention strategy, graft-versus-host disease prophylaxis, supportive care and post-transplant monitoring. Evidence-based care does not mean every patient receives the same regimen; it means decisions are made within a disciplined framework, using your diagnosis, risk features, treatment history and overall condition.

Technology supports the process at multiple points: laboratory testing to confirm diagnosis and assess molecular or cytogenetic risk, advanced imaging to evaluate disease burden and response, high-resolution tissue typing for donor selection, stem cell processing and preservation systems to prepare the graft, and electronic monitoring, blood bank support and infection surveillance during the admission. For you, the value is practical — more precise planning, closer monitoring, and care that adapts as your condition changes.

For patients travelling from abroad, the non-medical details matter almost as much as the clinical plan. Acibadem’s international patient services handle appointment coordination, medical record transfer, interpretation, travel-related guidance, hospital admission arrangements and communication with clinical departments, so that you and your family can concentrate on the treatment decisions rather than the logistics. Because transplant journeys are long, planning covers the whole arc — evaluation, any pre-transplant therapy, the admission, and the period of outpatient follow-up before it is safe to travel home.

Personalised planning is particularly important here because no two transplant pathways look alike. Some patients need additional chemotherapy before transplant. Others need a donor search, cardiac or pulmonary optimisation, infection treatment, dental clearance or nutritional strengthening first. Some are better served by a non-transplant therapy, or by delaying transplant until a defined disease milestone. A careful consultation identifies the safest and most appropriate sequence rather than forcing every patient down the same track.

Deciding whether — and when — to go ahead

A stem cell transplant is a major decision, but it is also a structured medical process that can be understood step by step. The most useful first move is a careful expert review: confirming the diagnosis, assessing disease risk, evaluating prior treatment response, reviewing donor or stem cell options, and determining whether transplant is appropriate now, later, or not at all. For many patients and families, that clarity does more to reduce anxiety than any amount of general reading.

Whatever centre you choose, a sound transplant recommendation should explain why the procedure is being considered, what alternatives exist, which risks are most relevant to you, what the inpatient and outpatient phases involve, how long you will need to stay near the centre, and what follow-up is required after returning home. Because transplant is a high-intensity treatment, clear expectations are part of safe care — and you are entitled to insist on them. Every situation is different: the right path depends on the disease, the timing, your overall health, donor availability and your own priorities, weighed with a transplant specialist who knows your case in full.